The genus of Ebolavirus
consists of at least six distinct Ebola virus species endemic to Africa. The Zaire species (EBOV) is associated with human Ebola hemorrhagic fevers (EHFs) with an extraordinary risk (40-90%) of mortality. EBOV is the causative agent for both the 2013-2015 epidemic in West Africa and the ongoing 2018-19 outbreaks in the Congo. There are no approved drugs for the treatment of EHF. A promising vaccine is likely to be approved in 2019, however, despite the inoculation of over 80,000 at-risk individuals during the 2018-19 Congo outbreak the toll of infected and confirmed deaths steadily climbed. Furthermore, the vaccine is specific for the EBOV species and unlikely to provide protection against other Ebola virus species, at least two of which, Sudan
(SUDV) and Bundibugyo
(BDBV), are associated with similar human EHF outbreaks. In association with the National Institute for Allergy and Infectious Disease (NIAID), Arisan Therapeutics has developed a novel chemical series of potent and broad-spectrum Ebola
virus cell entry inhibitors as confirmed in collaborative test studies with scientists at the University of Texas Medical Branch at Galveston and USAMRIID. Selected analogs further demonstrate attractive oral absorption and other drug-like properties in rodent animal models. Potent, broad-spectrum Ebola virus inhibitor compounds are currently under selection as candidates for efficacy testing in EHF animal models.